Browse ECM2

Summary
SymbolECM2
Nameextracellular matrix protein 2, female organ and adipocyte specific
Aliases matrix glycoprotein SC1/ECM2; Extracellular matrix protein 2
Chromosomal Location9q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix.
Domain PF13855 Leucine rich repeat
PF00093 von Willebrand factor type C domain
Function

Promotes matrix assembly and cell adhesiveness.

> Gene Ontology
 
Biological Process GO:0007160 cell-matrix adhesion
GO:0007409 axonogenesis
GO:0010810 regulation of cell-substrate adhesion
GO:0010811 positive regulation of cell-substrate adhesion
GO:0030198 extracellular matrix organization
GO:0031589 cell-substrate adhesion
GO:0043062 extracellular structure organization
GO:0045785 positive regulation of cell adhesion
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0061564 axon development
Molecular Function GO:0005178 integrin binding
GO:0005518 collagen binding
GO:0005539 glycosaminoglycan binding
GO:0008201 heparin binding
GO:0050839 cell adhesion molecule binding
GO:0070052 collagen V binding
GO:1901681 sulfur compound binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005614 interstitial matrix
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolECM2
Nameextracellular matrix protein 2, female organ and adipocyte specific
Aliases matrix glycoprotein SC1/ECM2; Extracellular matrix protein 2
Chromosomal Location9q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ECM2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolECM2
Nameextracellular matrix protein 2, female organ and adipocyte specific
Aliases matrix glycoprotein SC1/ECM2; Extracellular matrix protein 2
Chromosomal Location9q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ECM2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolECM2
Nameextracellular matrix protein 2, female organ and adipocyte specific
Aliases matrix glycoprotein SC1/ECM2; Extracellular matrix protein 2
Chromosomal Location9q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ECM2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.9490.0224
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.1180.246
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.8210.26
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1740.65
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3070.876
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 4701
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1410.8
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5280.652
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3790.783
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1180.932
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.8210.271
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4160.0156
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ECM2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.8014.80.00448
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.8014.80.00826
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolECM2
Nameextracellular matrix protein 2, female organ and adipocyte specific
Aliases matrix glycoprotein SC1/ECM2; Extracellular matrix protein 2
Chromosomal Location9q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ECM2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolECM2
Nameextracellular matrix protein 2, female organ and adipocyte specific
Aliases matrix glycoprotein SC1/ECM2; Extracellular matrix protein 2
Chromosomal Location9q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ECM2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ECM2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolECM2
Nameextracellular matrix protein 2, female organ and adipocyte specific
Aliases matrix glycoprotein SC1/ECM2; Extracellular matrix protein 2
Chromosomal Location9q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ECM2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolECM2
Nameextracellular matrix protein 2, female organ and adipocyte specific
Aliases matrix glycoprotein SC1/ECM2; Extracellular matrix protein 2
Chromosomal Location9q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ECM2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolECM2
Nameextracellular matrix protein 2, female organ and adipocyte specific
Aliases matrix glycoprotein SC1/ECM2; Extracellular matrix protein 2
Chromosomal Location9q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ECM2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolECM2
Nameextracellular matrix protein 2, female organ and adipocyte specific
Aliases matrix glycoprotein SC1/ECM2; Extracellular matrix protein 2
Chromosomal Location9q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ECM2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.